NCT01485848 - EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Ovarian Cancer Recurrent

Interventions

DRUG

EP-100

Pharmaceutical form:Solution Route of administration: Intravenous

DRUG

Paclitaxel

Pharmaceutical form:Solution Route of administration: Intravenous

Trial Locations (15)

40202

Investigational Site Number 840007, Louisville

45042

Investigational Site Number 840004, Middletown

58715

Investigational Site Number 840503, Bozeman

70433

Investigational Site Number 840010, Covington

71103

Investigational Site Number 840011, Shreveport

77030

Investigational Site Number 840006, Houston

94115

Investigational Site Number 840005, San Francisco

98112

Investigational Site Number 840403, Seattle

98115

Investigational Site Number 840003, Seattle

98273

Investigational Site Number 840103, Mount Vernon

98801

Investigational Site Number 840203, Wenatchee

99336

Investigational Site Number 840603, Kennewick

94904-2011

Investigational Site Number 840001, Greenbrae

97227-1191

Investigational Site Number 840008, Portland

98415-0299

Investigational Site Number 840303, Tacoma